Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy

• Status: Completed
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Sodium zirconium cyclosilicate (SZC) has been demonstrated for its serum potassium-lowering efficacy and safety in hyperkalemia hemodialysis patients.

However, the effects of SZC during the perioperative period remained unknown.

This experiment aimed to determine whether using SZC would impact the serum potassium levels in patients with maintenance hemodialysis after parathyroidectomy (PTX).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangdong Provincial People's Hospital

Criteria

Inclusion Criteria:

• Secondary Hyperparathyroidism (SHPT) is a common and severe manifestation of chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients. ESRD MHD with SHPT patients were recruited into this study

Exclusion Criteria:

• Patients with severe cardiovascular disease who cannot tolerate general anesthesia surgery were not included in this study.